Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China

Rebecca J Garten, Sheng-Han Lai, Jin-Bing Zhang, Wei Liu, Jie Chen, Xiao-Fang Yu

AIM: To study the virological and host factors influencing hepatitis C infection outcomes in heroin users in southern China.

METHODS: HCV RNA and associated factors were analyzed among 347 heroin users from Guangxi Zhuang Autonomous Region, southern China who were hepatitis C virus (HCV) EIA positive for two or more consecutive visits.

RESULTS: Using the COBAS AMPLICOR HCV TEST, a remarkably low HCV RNA negative rate of 8.6% was detected. After multivariate logistic regression analysis, HCV RNA clearance was significantly associated with the presence of HBsAg (OR = 8.436, P < 0.0001), the lack of HIV-1 infection (OR = 0.256, P = 0.038) and age younger than 25 (OR = 0.400, P = 0.029).

CONCLUSION: Our study suggests HCV infection among Chinese heroin users results in high levels of viral persistence even amidst factors previously found to enhance viral clearance. Prospective studies of a possible genetic component within the Chinese population and the pathogenicity of non-genotype 1 HCV infections are needed.
heroin trafficking routes into the province. It is not clear how widespread the HCV epidemic is in China. Little seroprevalence data exists, mostly from the major cities of Beijing, Shanghai and Hong Kong and to our knowledge, no studies on HCV RNA clearance in China have been done. Studies in Yunnan Province, which borders Guangxi Zhuang Autonomous Region in the west, have found high HCV co-infection rates in HIV-1 positive drug users. Previous epidemiological studies in Guangxi not only found similar high rates of HCV co-infection in HIV-1 positive drug users, but a high HCV prevalence (72%), incidence (37.8 per 100 person years) in all heroin users enrolled in the study. To determine the clearance rate of HCV RNA and study factors that influence clearance, serum from a large cohort of heroin users from Guangxi Zhuang Autonomous Region, southern China was qualitatively tested for HCV RNA.

MATERIALS AND METHODS

Study participants

Heroin users over the age of 18 in Guangxi Zhuang Autonomous Region, China are currently being followed in a study of behavioral and virological features of HIV-1 in injection drug users conducted at the Guangxi Provincial Health and Anti-Epidemic Center. Over 600 participants are being followed at study sites in Pingxiang and Binyang City in the Guangxi Zhuang Autonomous Region. Study participants from Pingxiang have been followed since September 1999 while participants from Binyang have been followed since January 2000. The informed consent procedure was described previously. Briefly, at each visit, participants underwent blood draw and personal interviews and were counseled on the results of their serological tests. Baseline and follow-up questionnaires entailed a brief medical history including sexually transmitted diseases, history of drug use, sexual history, ethnic and economical backgrounds. Blood was collected and centrifuged and the serum either underwent serological assays or was stored at -70°C. Samples were then shipped from Guangxi to our laboratory in Baltimore, MD for HCV RNA testing and further analysis.

SeroLogic assays

At the Guangxi Health and Anti-Epidemic Center in Nanning, the presence of HIV-1 antibody was determined by enzyme-linked immunosorbent assay (ELISA) using the Vironostika HIV-1 Microelisa System (Organon Teknika). All ELISA-positive samples were not considered HIV-positive until confirmation by HIV-1/2 Western blot immune assay manufactured by Gene Lab (Singapore). Positivity for Hepatitis B surface antigen (HBsAg) and antibody to Hepatitis B surface antigen (HBsAb) were determined by HBV ELISA (Xiamen Xinchung Scientific, Xiamen, China). Hepatitis C antibody was analyzed by the Ortho HCV Version 3.0 ELISA Test System (Ortho Diagnostic Systems, Raritan, NJ).

HCV RNA detection and determination of HCV serotypes and genotypes

Available sera from 347 participants who were HCV antibody positive for two consecutive visits (> 6 mo apart) were qualitatively tested for Hepatitis C RNA by the COBAS AMPLICOR HCV TEST KIT, sensitivity > 50 IU/mL (Version 2.0, Roche Diagnostics). Hepatitis C genotypes were determined for samples found HCV RNA negative using the Murex HC03 ELISA (Abbott Diagnostics, England). DNA for HCV genotyping was extracted from 100 µL of serum using the QIAamp Viral RNA kit (QIAGEN Inc, Valencia, CA). Reverse transcription and nested PCR was performed using primers to conserved regions of Core and E1 as previously described. After purification with the QIAQuick PCR Purification kit (QIAGEN Inc, Valencia, CA), samples were sequenced using the internal forward primer on an automated sequencer (PRISM, version 2.1.1; ABI, Foster City, CA). Sequences were compiled using the BioEdit program, version 4.7 (T. Hall, North Carolina State University, Raleigh) and genotypes were assigned after alignment with known HCV genotypes as previously described.

Statistical analysis

Univariate logistic regression analyses were first performed to explore the crude associations between the clearance of HCV and related factors, including age, length of drug use, frequency of drug use, injection drug use, HIV-1 Ab, HBsAb, HBsAg, study site, ethnicity and gender. Variables with a P < 0.1 in the univariate model were then put into a multiple logistic regression model. Those that ceased to be significant in the multivariate model, P > 0.05, were eliminated in a stage-wise manner, yielding a final model in which all variables were independently associated with the clearance of HCV. P-values reported are two-sided. The age, frequency of drug use and length of drug use closest to the overall sample mean within a factor of five were used in the model.

RESULTS

A total of 347 study participants who were HCV EIA positive for two or more consecutive study visits were included in this study, 127 from Pingxiang City and 220 from Binyang City. Pingxiang City is in southern Guangxi and borders Vietnam while Binyang City is centrally located within the province. Survey and serology results from the study visit of HCV RNA analysis are listed in Table 1. This subset of the Guangxi cohort is predominantly male (96.25%) with a mean age of 27 (range 19-50). Two main ethnic groups are present in Guangxi, Han and the Zhuang minority. Approximately 67% of the study group is Han and 29% Zhuang. Less than half of the participants are married (32%). Over 90% of the participants have a middle school or lower level of education.

Approximately 93% of the heroin users admit to injection drug use (Table 1). Over half admit to sharing needles (data not shown). The participants have been injection drug users for an average of about 5 years (Table 1). The study group uses heroin at an average frequency of 74 times per month. Along with being HCV EIA positive, 25.94% of the study participants are also HIV Ab positive.
13.26% are HBV surface antigen positive (HBsAg) and 42.65% are antibody positive for the HBV surface antigen (HBsAb). Of the 347 consecutively HCV EIA positive samples tested, only 30 had undetectable levels of HCV RNA (less than 50 IU/mL) resulting in an HCV RNA clearance rate of 8.6% (Table 1).

Results of univariate logistic regression analyses and final multivariate logistic regression analyses for Hepatitis C Viral RNA clearance are shown in Table 2. Univariate analysis revealed HCV RNA clearance to be associated with age younger than 25 (OR = 0.472), lack of HIV-1 infection (OR = 0.294), presence of HBsAg (OR = 7.793), lack of HBsAb (OR = 0.308), female gender (OR = 3.411) and acknowledgement of injection drug use (OR = 0.441). In the final model, only three factors were independently associated with HCV RNA clearance; being HBsAg positive (OR = 8.436, P < 0.0001), lacking HIV-1 infection (OR = 0.256, P = 0.038) and age younger than 25 (OR = 0.400, P = 0.029).

A comparison of previously published HCV RNA clearance rate can be found in Table 3. Our HCV RNA clearance rate is most similar to African American injection drug users in the Baltimore ALIVE cohort[3], but remarkably less than the remaining studies listed.

### DISCUSSION

Injection drug practices in Guangxi Zhuang Autonomous Region, China continue to efficiently spread HCV, HIV and HBV resulting in large numbers of co-infections and multi-infections, the full impact of which has yet to be determined. Analysis of this cohort found a very low spontaneous HCV clearance rate (8.6%) among heroin users who have been HCV EIA positive for two or more consecutive study visits. The natural history of HCV in Chinese individuals has not been studied to this extent before.

Hepatitis C viral clearance was strongly associated with co-infection by the hepatitis B virus, specifically participants currently HBsAg positive. Other cohorts have seen trends between HBsAg positivity and HCV clearance[3,23], but none with an association as convincing as is shown in our cohort. Previous studies of HBV and HCV co-infections have revealed viral interference between these hepatotropic viruses resulting either in one dominant virus[43] or in some cases resolution of both infections[44]. The exact mechanism of this interference is not known, although data suggest it is the result of inhibition of replication by viral proteins[45,46]. It is also plausible that the existing activation of non-specific immune responses within the liver during the current HBV infection enhances the clearance of the HCV infection.

HCV is now a major opportunistic infection for those with co-infected HIV-1[47]. Previous studies have shown that co-infections with HIV and HCV do not increase the progression to AIDS[48], but do increase the HCV viral load and progression to end-stage liver disease (ESLD)[49,50]. Two separate subtypes of HIV, A/E and a B/C recombinant, were likely to enter Guangxi Zhuang Autonomous Region in 1996[51]. With high HCV prevalence and incidence rates, almost all injection drug users in Guangxi who become HIV-1 positive will be co-infected with HCV. This study found a significant association between HIV co-infection, defined by the presence of HIV-1 antibody, and the inability of the individual to clear HCV RNA. Only 3/90 HIV-1 antibody positive individuals were able to clear their HCV RNA. Two of these participants were new HIV-1 seroconverters and the third was HBsAg positive (data not shown). The mechanism of how HIV-1 infection inhibits HCV RNA clearance is likely due to immune suppression caused by HIV-1. It is less likely that the two HIV-1 seroconverters who cleared HCV RNA were immuno-compromised (data not shown). Thomas et al did not see a significant association between HIV-1 co-infection and HCV clearance in the ALIVE cohort until HIV-1 infected people were broken down by CD4 levels[3].
Age of the individual also affected the HCV clearance rate in our cohort. A meta-analysis by Mathei et al found a linear relationship between mean age and HCV RNA clearance rates. The higher prevalence of HCV RNA in older individuals was suggested as a result of continuous re-exposure to HCV for a prolonged period of time. The ages found in our cohort are much younger than previous HCV studies where HCV RNA clearance rates were less than 15%.[3,20] We attempted to address whether our high levels of HCV RNA persistence were due to the length and frequency of drug use, but these factors proved non-significant.

HCV genotype 1 has been considered a more aggressive genotype, associated with lower clearance rates, decreased susceptibility to current treatments[32-34] and in a few cases, associated with a faster progression of HIV disease.[31] Many HCV cohort studies, including the ALIVE cohort in Baltimore are primarily genotype 1 infections.[9] Examination of our cohort found three major HCV subtypes present in chronic infections, genotypes 6a (38%), 3b (37%) and 1a (19%).[32] It is unclear whether HCV genotypes in our cohort are responsible for the low HCV RNA clearance rate.

Age, HBsAg positivity and lack of HIV-1 co-infection were the most significant factors resulting in HCV RNA clearance. In comparison with the ALIVE cohort,[3] our lower age, lower prevalence of HIV-1 and higher prevalence of HBsAg, would predict higher rates of HCV RNA clearance than was seen. After removing HIV-1 and HBsAg positive individuals, only 15 of the remaining 221 participants underwent HCV clearance, at a rate of 6.8% (data not shown). This suggests that other host and viral factors are present in the Guangxi cohort resulting in high rates of HCV persistence. Studies of the ALIVE cohort by Thomas et al found the lower HCV RNA clearance levels in African American injection drug users to be linked to differences in certain HLA-frequencies.[3,25] There is also speculation of differences in TH1/TH2 cytokine balances between Caucasian and African Americans.[53] Whether HLA or cytokine profiles of Chinese individuals account for the low HCV RNA clearance rates has yet to be seen.

Injection heroin use in China is rapidly distributing HCV, HBV and HIV. The natural history of HCV in Chinese heroin users results in little spontaneous clearance of HCV RNA. Current HIV infection further debilitates the individual's ability to control HCV infection. And although HBV is endemic in China and viral interference between HBV and HCV may eliminate one of the hepatotropic viruses, it may not decrease the possibility for further liver disease. Further studies within the Guangxi

| Factor              | Number (% clearance) | Univariate Adjusted OR (95% CI) | Final multivariate model Adjusted OR (95% CI) | P       |
|---------------------|----------------------|---------------------------------|-----------------------------------------------|---------|
| Age (yr)            |                      |                                 |                                               |         |
| ≤ 25                | 125 (13.6)           | 1.0                             | 1.0                                           | 0.029   |
| > 25                | 222 (5.9)            | 0.472 (0.221-1.006)             | 0.400 (0.176-0.909)                           |         |
| HIV Ab status       |                      |                                 |                                               |         |
| Negative            | 257 (10.5)           | 1.0                             | 1.0                                           | 0.038   |
| Positive            | 90 (3.3)             | 0.294 (0.087-0.993)             | 0.256 (0.071-0.924)                           |         |
| HBsAg status        |                      |                                 |                                               |         |
| Negative            | 301 (5.3)            | 1.0                             | 1.0                                           |         |
| Positive            | 46 (30.4)            | 7.793 (3.484-17.430)            | 8.436 (3.646-19.520)                          | < 0.0001|
| HBsAb status        |                      |                                 |                                               |         |
| Negative            | 199 (12.1)           | 1.0                             |                                               |         |
| Positive            | 148 (4.1)            | 0.308 (0.123-0.744)             |                                               |         |
| Gender              |                      |                                 |                                               |         |
| Male                | 334 (8.1)            | 1.0                             |                                               |         |
| Female              | 13 (23.1)            | 3.411 (0.885-13.143)            |                                               |         |
| Location            |                      |                                 |                                               |         |
| Binyang             | 220 (9.1)            | 1.0                             |                                               |         |
| Pingxiang           | 127 (7.9)            | 0.855 (0.387-1.888)             |                                               |         |
| Ethnicity           |                      |                                 |                                               |         |
| Zhuang minority     | 115 (8.7)            | 1.0                             |                                               |         |
| Han                 | 232 (8.6)            | 0.991 (0.448-2.192)             |                                               |         |
| Injection drug use  |                      |                                 |                                               |         |
| Yes                 | 323 (9.0)            | 1.0                             |                                               |         |
| No                  | 24 (4.2)             | 0.441 (0.057-3.384)             |                                               |         |
| Length of drug use  |                      |                                 |                                               |         |
| < 5 yr              | 176 (10.8)           | 1.0                             |                                               |         |
| ≥ 5 yr              | 171 (6.4)            | 0.568 (0.262-1.233)             |                                               |         |
| Frequency of drug use|                     |                                 |                                               |         |
| < 75 times per month| 217 (7.4)            | 1.0                             |                                               |         |
| ≥ 75 times per month| 130 (10.8)           | 1.516 (0.714-3.219)             |                                               |         |

OR: Odds ratio; CI: Confidence Interval; HCV: Hepatitis C virus; HIVAb: HIV-1 antibody; HBsAg: Hepatitis B surface antigen; HBsAb: Antibody to hepatitis B surface antigen.
A low rate of HCV clearance was found in injection drug users of Chinese ethnicities. The majority of HCV infections were non-genotype 1 and many of the participants had current or previous co-infections with Hepatitis B viruses. Together, these factors have previously been found to increase the level of viral clearance, suggesting other factors in the cohort are driving the low rate of viral clearance.

Innovations and breakthroughs

This research highlights the need for further studies of HCV infections in Chinese ethnicities which concentrate on the immunogenetics of the host.

Applications

This paper describes the rate of hepatitis C viral RNA clearance in heroin users from South China and analysis of factors associated with it. The authors found a remarkably low rate of hepatitis C viral RNA clearance in the cohort and some possibly related factors. The data presented are epidemiologically important, and the authors discussed the results appropriately.

REFERENCES

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 1989; 244: 359-362
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* 1989; 244: 362-364
3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA* 2000; 284: 450-456
4. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *Hepatology* 1999; 29: 908-914
5. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, Puel J, Pascal JP, Duffaut M, Abbal M. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. *Gastroenterology* 1997; 113: 1675-1681
6. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. *Liver Transplantation* 1999; 5: 489-494
7. Yee TT, Griffinon A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophiliac patients infected between 1961 and 1985. *Gut* 2000; 47: 845-851
8. Alter HJ, Conry-Cantilena C, Melponder J, Tan D, Van Radeen M, Herion D, Lau D, Hoofnagle JH. Hepatitis C is asymptomatic blood donors. *Hepatology* 1997; 26: 296-335
9. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. *N Engl J Med* 1999; 340: 1228-1233
10. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Baslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999; 341: 556-562
11. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Pincino F. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C and D viruses in patients with chronic hepatitis. *Hepatology* 2000; 32: 1106-1110
12. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. *J Exp Med* 2000; 191: 1499-1512
13. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL, Walker

Table 3  HCV RNA clearance rates among previously published cohort studies

| Principal investigator | Cohort | Number tested | HCV RNA clearance rate (%) | Percent HIV Ab+ | Percent HBsAg + |
|------------------------|--------|---------------|---------------------------|----------------|----------------|
| This study Thomas[6]   | Chinese IDU | 347 | 8.71 | 25.9% | 13.3% |
|                        | African | 729 | 9 | ND |
|                        | American IDU | 44 | 36.0 | ND |
|                        | Overall | 773 | 10.9 | 45.7% | 3.5% |
| Alric[5]               | Caucasian French | 123 | 25 | ND |
| Mintorn[6]             | Caucasian English | 172 | 20.3 | ND |
| Yee[7]                 | English | 200 | 14 | 40.3% | ND |
| Alter[8]               | American blood Donors | 248 | 14 | ND |
|                        | (42% IDU) | 704 | 44.6 | ND |
| Kenny-Walsh[9]         | Irish women Non-Hispanic African | 196 | 14.0 | ND |
| Alter[9]               | American | 119 | 32.0 | ND |
|                        | Caucasian Hispanic Americans | 132 | 26.0 | ND |
|                        | NHANES Overall | 447 | 26.1 | ND |
|                        | Italian liver Patients | 336 | 21.2 | 28% |

1: HCV RNA by Roche AMPLICOR HCV Qualitative Assay-Sensitivity > 50 IU/mL; 2: HCV RNA by In-house RT-PCR- Sensitivity Unknown; 3: HCV RNA by HEPA-Check C - Sensitivity Unknown; 4: HCV: Hepatitis C virus; IDU: Injection drug user; HIV: Human immunodeficiency virus 1; HBsAg: HBV surface antigen; ND: Not determined.

cohort and other Chinese Provinces will better define the pathogenesis of HCV in Chinese ethnicities and non-genotype 1 infections. In order to decrease the spread of HIV-1 and HCV, education on safe-needle practices and the illnesses transmitted by injection drug use is urgent in China.

ACKNOWLEDGMENTS

We would like to thank Lara Sanders at Abbott Diagnostics for her assistance in performing the HCV serotyping.

COMMENTS

Background

Hepatitis C virus (HCV) is quickly spread through injection drug use. A proportion of individuals infected with HCV undergo viral clearance while the remaining individuals develop a chronic infection which can lead to cirrhosis, hepatocellular carcinoma and the need for a liver transplant. Injection drug use is a major risk factor for HCV infections. This research studies the rate of HCV clearance in injection drug users from Southern China and the potential associated factors for clearance.

Research frontiers

This research studies HCV clearance in Chinese ethnicities with non-genotype 1 infections.
CM. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. *Immunity* 2001; 15: 863-895

Cooper S, Erickson AL, Adams EJ, Kropoj J, Weiner AJ, Chien MC, Zachoval R, Parham P, Walker CM. Analysis of a successful immune response against hepatitis C virus. *Immunity* 1999; 10: 439-449

Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest* 1996; 98: 706-714

Diepolder HM, Zachoval R, Hoffman JM, Jung MC, Gerlach T, Pape GR. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. *J Mol Med* 1996; 74: 583-588

Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiari M, Cerny A, Pape GR. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. *J Infect Dis* 2000; 181: 1528-1536.

Rosen HR, Miner C, Sasaki AW, Lewinson DM, Conrad AJ, Bakke A, Bouwer HG, Hinrichs DJ. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. *Hepatology* 2002; 35: 190-198

Diepolder HM, Gerlach JT, Zachoval R, Hoffmann JM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape GR. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. *J Virol* 1997; 71: 6011-6019

Mathei C, Buntinx F, Van Damme P. Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? *J Infect Dis* 2001; 184: 659-660

Orland JR, Wright TL, Cooper S. Acute hepatitis C. *Hepatology* 2001; 33: 321-327

Inoue G, Honda K, Michioka K, Oji M. Hepatitis C virus clearance is prominent in women in an endemic area. *J Gastroenterol Hepatol* 2000; 15: 1054-1058

Thomas DL, Rich JD, Schuman P, Smith DK, Astemborski JA, Nolt KR, Klein RS. Multicenter evaluation of hepatitis C RNA clearance is prominent in women in an endemic area. *J Gastroenterol Hepatol* 2000; 15: 1054-1058

Vejaesa S, Songvisal S, Tanwandees T, Rachanun S, Chatangkel R, Dharakul T. A association with hepatitis C virus infection. *Hepatol Int* 2001; 18: 16-21

Thurz M, Valloport R, Goldin R, Topol C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. *Lancet* 1999; 354: 2119-2124

Allic F, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, Fauchart R, Dufau M, Alfalf M, Genedre C. Major A major determinant of viral status, but not fibrotic stage, in hepatitis C virus infection. *J Virol* 1997; 113: 1675-1681

Lechmann M, Schneider EM, Giers G, Kaiser R, Dumoulin FL, Sauerburch T, Spengler U. Increased frequency of the HLA-DR15 (B*1501) allele in German patients with self-limited hepatitis C virus infection. *Eur J Clin Invest* 1999; 29: 337-343

Farc P, Shimada A, Coiana A, Diaz G, Peddis G, Melpolder JC, Straeb PJ, Dufau M, Alfalf M, Genedre C. Major determinant of viral status, but not fibrotic stage, in hepatitis C virus infection. *J Virol* 1997; 113: 1675-1681

Lechmann M, Schneider EM, Giers G, Kaiser R, Dumoulin FL, Sauerburch T, Spengler U. Increased frequency of the HLA-DR15 (B*1501) allele in German patients with self-limited hepatitis C virus infection. *Eur J Clin Invest* 1999; 29: 337-343

Farc P, Shimada A, Coiana A, Diaz G, Peddis G, Melpolder JC, Straeb PJ, Dufau M, Alfalf M, Genedre C. Major determinant of viral status, but not fibrotic stage, in hepatitis C virus infection. *J Virol* 1997; 113: 1675-1681

Zeil PN. Clinical significance of hepatitis C virus genotypes. *Clin Microbiol Rev* 2000; 13: 223-235

Powlowski JM, Tsakiris A, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. *J Infect Dis* 1995; 171: 1607-1610

Martinot Peignon M, Roudot-Thoraval F, Mendl I, Coste J, Izopet J, Duverlie G, Payan C, Pawlotsky JM, Derfer C, Bogard M, Gerolami V, Halfon P, Buisson Y, Fouqueray B, Loiseau P, Lamoril J, Lefere JJ, Marcellin P. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. *The GEMHEP.* *J Viral Hepat* 1999; 6: 435-443

Kishihara Y, Furuyso N, Kashiyagi K, Mitsutake A, Kashiyagi S, Hayashi J. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. *J Infect Dis* 2001; 184: 1114-1119

Kamal SM, Rasenack J, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, Ezzat W, Koziel M. Acute hepatitis C without and with and with schistosomiasis: correlation with hepatitis C-specific CD4+ T-cell and cytokine response. *Gastroenterology* 2001; 121: 646-656

Lai S, Chen J, Celentano D, Page JB, Lai H, Yang J, Liu W, McCoy CB, Yu XF. Adoption of injection practices in heroin users in Guangxi Province, China. *J Psychoactive Drugs* 2000; 32: 285-292

Beyrer C, Razak MH, Lisam K, Chen J, Liu W, Yu XF. Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS 2000; 14: 75-83

Yu XF, Chen J, Shao Y, Beyrer C, Liu B, Wang Z, Liu W, Yang J, Liang S, Viscidi RP, Gu J, Guri-Glass G, Lai S. Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. *J Acquir Immune Defic Syndr* 1999; 22: 180-188

Zhang C, Yang R, Xia X, Qin S, Dai J, Zhang Z, Peng Z, Wei T, Liu H, Pu D, Luo J, Takebe Y, Ben K. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. *J Acquir Immune Defic Syndr* 2002; 29: 191-196

Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. *Clin Infect Dis* 2005; 41 Suppl 1: S18-S24

Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL, Ambros D. Genetic epidemiology of hepatitis C virus in China. *J Virol* 2000; 182: 698-707

Clayton D, Hills M. Statistical methods in epidemiology. New York: Oxford Press, 1993: 229-233

Liauw YF, Chien RN, Chen TJ, Sheen IS, Chu CM. Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis B virus infection. *J Med Virol* 1992; 37: 294-297

Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. *Liber* 1999; 19: 348-353

Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Huh-7 cells. *J Virol* 1993; 67: 5825-5832

Zarski JP, Bohn B, Bastle A, Pawlotsky JM, Baud M, Bost Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses. *J Hepatol* 1998; 28: 27-33

Sulkowski MS, Mest EE, Seef LB, Thomas BD. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. *Clin Infect Dis* 2000; 30 Suppl 1: S77-S84

Dorrucci M, Pezzotti P, Phillips AN, Leprì AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. *Italian Seroconversion Study.* *J Infect Dis* 1995; 172: 1503-1508

Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren
50 Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *J Infect Dis* 2001; 183: 1112-1115

51 Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. *J Infect Dis* 1997; 175: 164-168

52 Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, Yu XF. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. *Int J Epidemiol* 2004; 33: 182-188

53 Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. *J Med Virol* 2001; 65: 510-516